ENB 105
Alternative Names: ENB-105Latest Information Update: 26 Aug 2024
Price :
$50 *
At a glance
- Originator EnnovaBio
- Class Anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colitis; Inflammatory bowel diseases
Most Recent Events
- 31 Jul 2024 Phase-I clinical trials in Colitis (Unspecified) prior to July 2024 (EnnovaBio pipeline, July 2024)
- 31 Jul 2024 Phase-I clinical trials in Inflammatory bowel diseases (Unspecified) prior to July 2024 (EnnovaBio pipeline, July 2024)